Comparison between Ovalbumin and Ovalbumin Peptide 323-339 Responses in Allergic Mice: Humoral and Cellular Aspects

L.-Z. Sun*, S. Elsayed*, T. B. Aasen†, T. Van Do*,†, N. P. Aardal§, E. Florvaag*,†,‡ & K. Vaali*

*Allergy Research Group, Institute of Medicine, University of Bergen, Bergen, Norway; †Department of Occupational Medicine; ‡Laboratory of Clinical Biochemistry; and §Department of Pathology, Haukeland University Hospital, Bergen, Norway

Received 26 October 2009; Accepted 21 January 2010

Correspondence to: L.-Z. Sun, Institute of Medicine, University of Bergen, N-5021 Bergen, Norway. E-mails: lizhi.sun@gmail.com; lizhi.sun@med.uib.no

Abstract

Ovalbumin (OVA) is widely used in allergy research. OVA peptide 323-339 has been reported to be responsible for 25–35% of isolated BALB/c mouse T-cell response to intact OVA. An investigation of whether OVA and OVA 323-339 molecules can induce equivalent in vivo and in vitro immune responses was conducted. Eight-week-old BALB/c mice were randomly divided into three groups: OVA, OVA 323-339 and saline. On days 0, 7, 14, mice were intraperitoneally injected with 25 μg OVA or OVA 323-339 absorbed on 300 μg Alum, or saline; on days 21–23, all groups were challenged intranasally with either 20 μl of 1% OVA, 1% OVA 323-339 or saline. On day 28, after killing, splenocytes were isolated and cultured under the stimulus of each allergen or medium. Evaluated by hematoxylin/eosin and major basic protein immunohistochemical stainings, OVA and OVA 323-339 induced similar lung inflammation. Interestingly, significant serum total IgE and OVA-specific IgE were observed in OVA mice when compared to saline control. OVA 323-339 mice showed higher serum OVA-specific IgE, OVA 323-339-specific IgE, IL-4 and lower IFN-γ similar to OVA mice. The proliferative response to OVA was found in cultured splenocytes of both OVA and OVA 323-339 mice, while the similar proliferative response to OVA 323-339 was only observed in the splenocytes of OVA 323-339-sensitized and challenged mice. Although OVA 323-339 induced a Th2-like response in the mouse model as did OVA, OVA 323-339 has clearly limited immunogenic potency to activate OVA-sensitized and challenged mouse splenocytes, unlike OVA.

Introduction

Hen eggs are an essential ingredient in a variety of processed food products and are therefore difficult to eliminate from the diet. The proteins of hen’s egg white, like ovalbumin (OVA), frequently induce hypersensitivity symptoms among egg allergic individuals [1, 2].

OVA, which constitutes approximately 58% (w/w) of the entire hen’s egg white extract, is the most dominant ingredient of the five major allergens of egg white and is universally used as the main allergen in establishing different animal models of asthma, food and dermal allergy. OVA’s allergenic epitopes were mainly determined by the primary structure and are dependent on a certain peptide chain length [1, 3, 4]. Among many egg white proteins, OVA 323-339 and OVA 1-10, as well as intact OVA, were reported to encompass B-cell epitopes which were recognized by specific IgE antibodies. The OVA 323-339 sequence was also demonstrated to include CD4+ T cell epitopes, which were restricted by the MHC class I-Aβ molecule in mice [2, 5, 6], and was considered to encompass at least one B cell epitope [7, 8]. Furthermore, the OVA-specific T-cell line from hen egg allergic patients was able to recognize OVA 323-339 presented by HLA-DR10 [2, 9].

OVA 323-339 has been used extensively to study the nature of class II MHC-peptide binding and T-cell activation [10–14]. It has been reported that OVA peptide 323-339 was responsible for 25–35% of the BALB/c T-cell response to the intact OVA, and it is highly probable that OVA 323-339 was closely related to the naturally created peptide by the antigen presenting cell (APC) during OVA processing [4, 5, 8, 15]. However, Janssen et al. [16] demonstrated that the immunodo...
minant epitope of OVA, e.g. OVA 323-339, accounts for 50% of the OVA-specific B-cell response and 60–70% of the OVA-specific T-cell response. So far, there is only a small amount of available information on in vivo immune responses in OVA 323-339-treated animals. Kearney et al. [17] reported that systemic injection of OVA or OVA 323-339 in a T-cell transfer model induced a rapid and strong, but transient DO11.10 T-cell proliferation. They also described that the induction of more local and less transient response by the subcutaneous administration of OVA 323-339 in Freund's Complete Adjuvant resulted in a significantly enhanced T-cell response upon in vitro stimulation with OVA 323-339 [17, 18]. Knowledge on the immunogenicity of allergens is important and mandatory for establishing modern therapeutic methods for the treatment of allergy.

In this study, our aim was to investigate whether synthetic OVA peptide 323-339 has parallel in vivo immunogenicity with OVA in a BALB/c mouse allergy model. In addition, using these OVA or OVA 323-339-sensitized and challenged mice, in vitro splenocyte stimulation was examined.

Materials and methods

Allergens. Ovalbumin (OVA, electrophoretic purity 99%, lot 81F-8230) was purchased from Sigma (St. Louis, MO, USA), and the OVA peptide with the amino acid residues 323-339 was synthesized using semi-automatic peptide synthesizer (LKB Biochrom, Ltd, Cambridge, England) as described by Johnsen and Elsayed [4]. Briefly, the solid-phase peptide synthesis of OVA 323-339 was prepared manually, and the preparations were cleaved from the resin by the use of HBr and trifluoroacetic acid (TFA). The purification of the peptides by gel filtration chromatography was performed using Biogel P2 column (dimensions 61 x 1 cm) with 200–400 mesh resin (Bio-Rad, Richmond, CA, USA) and the void volume peak contained the peptide in question. High-performance liquid chromatography was performed using an ion-exchange column (Bio Siol TSK DEAE 2-SW, dimension 250 x 4.6 mm; Bio-Rad) with a routine solvent system (20 mmol/l Tris/HCl, and 20 mmol/l Tris/HCl in 500 mmol/l NaCl) at pH 6.2, which was run at a linear gradient ratio for 14 min. Aliquots of 100 µg peptide were originally run, and the absorbance was monitored at 220 nm. The initial concentration of the peptides (2 µM) was used in sixfold serial dilutions for examining their activity.

Animals. Female BALB/c mice (8-week old) were obtained from Taconic (4140 Borup, Denmark) and housed at the Vivarium animal house, Haukeland University Hospital (Bergen, Norway). They were kept in a conventional animal room with 12-h dark/light cycles and received water and pelleted pathogen-free food.

**Figure 1** Protocols of the in vitro and in vivo studies. Mice were sensitized with intraperitoneal injection (IP) and then challenged with the respective allergens or saline intranasally (IN). Three different study groups were used: Pep (mice sensitized and challenged with OVA 323-339), OVA and saline. The Pep group is presented as an example to explain the protocols.

(Special Diet Services, Witham, Essex, England) ad libitum. The experimental procedure was approved by the local Ethical Committee for Animal Experiments in Bergen, Norway.

**In vivo sensitization and challenge of mice.** Fifty-one 8-week-old female BALB/c mice were randomly divided into three groups: OVA, OVA 323-339 and saline. They were intraperitoneally injected with 25 µg OVA or OVA 323-339 absorbed on 300 µg Alum (Imject®, lot E164 107, Pierce Biotechnology Inc., Rockford, IL, USA) or saline on days 0, 7, 14. On days 21–23, all groups were challenged intranasally with 20 µl of 1% OVA, 1% OVA 323-339 and saline, respectively. The protocol is illustrated in Fig. 1.

**Serum and bronchoalveolar lavage fluid (BALF) collection.** On day 28, the mice were given intraperitoneal injections with 50 mg/kg of Pentothal (Abbott Scandinavia AB, Solna, Sweden) and killed by right ventricular exsanguinations. The blood was collected and left to coagulate at room temperature for at least 30 min, and then centrifuged at 1000 g for 10 min. The serum samples were stored at −20 °C until use. After right ventricular exsanguinations, the trachea was cannulated with a 20G catheter (Vasofix®, B.BRAUN Melsungen AG, Melsungen, Germany), and the lungs were lavaged three times with aliquots of 0.5 ml of sterile saline per mouse. The collected lavage fluid was centrifuged at 400 g, and the supernatant was stored at −20 °C for cytokine and antibody analyses.

**Histology.** The lung was inflated with similar volume of phosphate-buffered 10% formaldehyde (600 µl) at a constant pressure and then immediately soaked in the same solution for approximately 24 h. Longitudinally oriented trachea, a horizontal slice from the middle zone of the single left lobe of the lung was then embedded in paraffin, 5-µm sections were cut and stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO, USA). Bronchial airway wall thickness was measured with the method described previously [19].

© 2010 The Authors
Journal compilation © 2010 Blackwell Publishing Ltd. Scandinavian Journal of Immunology 71, 329–335
Immunohistochemistry. For the detection of extracellular major basic protein (MBP) in tissues, rabbit polyclonal antiserum to mouse MBP was used, which was kindly provided by Dr. James Lee (Mayo Clinic, Scottsdale, AZ, USA). Anti-MBP was diluted 1:300 in antibody dilution buffer (DakoCytopation, CA, USA) and incubated for 1 h with 5-μm paraffin sections at room temperature. Cross-reactivity was blocked with HP-block (DakoCytopation), followed by a reaction with horseradish peroxidase (HRP)-linked swine anti-rabbit diluted 1:500, and then the antibody-captured cells were detected with 3, 3'-diaminobenzidine (DAB). Sections were counterstained with hematoxylin.

Quantification of total IgE. Total IgE was measured by mouse ELISA quantification kits (Bethyl Laboratories, Montgomery, TX, USA) as previously described [19]. In brief, the plates were coated with affinity-purified goat anti-mouse IgE overnight at 4 °C and then blocked with bovine serum albumin in 10-mM phosphate-buffered saline (PBS) at pH 7.4. The threefold diluted serum samples or undiluted BALF samples and appropriate dilutions of a standard IgE preparation were used. The bound IgE was detected with polyclonal goat anti-IgE antibody (incubation for 1 h at 37 °C), followed by HRP-conjugated goat anti-mouse antibody.

The plates were developed by the addition of tetramethylbenzidine (TMB) and read with an ELISA plate reader (Labsystem Multiskan Bichromatic, Helsinki, Finland) at a wavelength of 450 nm. The kit detection range was 3.9–250 ng/ml.

Detection of OVA-323-339-specific IgE, IgG1 and IgG2a in serum. Specific immunoglobulin were assayed by in-house ELISA as previously described [20]. In brief, microtitre plates were coated with OVA (fraction V, Sigma, 2 μg/ml) or OVA 323-339 in 0.05 M NaHCO3 buffer pH 9.6, and the serum samples were diluted 1:5 for OVA-specific IgE, 1:10 for IgG2a, and 1:200 for IgG1 in 10-mM phosphate buffer solution. Commercially available biotin-labelled anti-mouse isotype-specific secondary antibodies were then diluted to 2 μg/ml (BD Pharmingen, San Jose, CA, USA).

As for the detection of specific IgE to OVA 323-339, microtitre plates were coated with rat anti-mouse IgE (clone R35-72, 2 μg/ml), and the serum samples were diluted 1:10 in 10 mM phosphate-buffered saline. Biotinylated OVA 323-339-BSA conjugate was then applied. The biotinylations were performed according to the manufacturer’s instructions (EZ-Link NHHS-PEO4-Biotinylation Kit, Pierce, Biotechnology, Rockford, IL, USA) [3, 20].

Streptavidin-horseradish peroxidase was diluted into 1:4000 (BD Pharmingen), and peroxidase substrate reagents (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) were used for immunodetection.

The results were measured at 405 nm wavelength (Spectra max plus, Sunnyvale, CA, USA) and expressed as optical density (OD).

Determination of cytokine levels. IL-4 and IFN-γ in serum and BALF samples were measured with commercial ELISA kits (R&D systems, Minneapolis, MN, USA) according to the manufacturer’s protocols [19].

Cell culture. The spleens were minced into small pieces, splenocytes were dissected free and then collected from interface after Ficoll-paque (GE Healthcare, Uppsala, Sweden) centrifugation. The viability of the collected cells was ≥95% by the use of trypan blue exclusion method. Separated splenocytes were cultured on 24-well cell culture clusters with 100 μl or 200 μl of saline or allergens (10 μg/ml or 20 μg/ml) in RPMI-1640 (Gibco BRL, Paisley, UK) at 37 °C 5% CO2, final volume of 2 ml. Three days after initiating the culture, 100 μl of recombinant IL-2 (rIL-2) (1 μg/ml) was added to each well. On day 4, 200 μl of cells (2.5 × 105 cells/well) in duplicate were cultured in 96-wells overnight by adding 20 μl of 0.05 mCi/ml [3H]-thymidine.

Measurement of splenocyte proliferation. Following stimulation, the cultures were investigated for primary proliferation responses as measured by 3H-thymidine uptake. The cultured well contents were then harvested onto filter mats using a cell harvester. The discs representing each well were transferred from the filter mats into 5-ml volumes of scintillation fluid, and the incorporation of [3H] thymidine into the cultured cells was measured using standard scintillation counting procedures by 1414 liquid scintillation counter (Wallac, Turku, Finland). The results were expressed as counts per minute (cpm) and stimulation index (SI).

Statistics. Data were presented as mean ± SD. Statistical analyses were performed with ANOVA using saline as a reference category, and followed by post hoc tests with adjustments for multiple testing by the approach of Dunnett’s T3 where equal variances within groups are not assumed. Overall values P < 0.05 were considered significant. All tests were two-tailed, and the data were analyzed with SPSS statistical software (SPSS Inc., Chicago, IL, USA).

Results

Local inflammatory cell infiltration and airway wall remodelling

The saline control mice demonstrated normal lung morphology. In contrast, an eosinophil-dominant inflammatory cell infiltration including macrophages, a few neutrophils and lymphocytes were mainly observed around bronchi and vessels in the OVA- and OVA 323-339-treated mice. The hypertrophia of cells lining the airways was also shown in lung tissues with hematoxylin-eosin

© 2010 The Authors
Journal compilation © 2010 Blackwell Publishing Ltd. Scandinavian Journal of Immunology 71, 329–335

L.-Z. Sun et al.
Humoral and Cellular Aspects of OVA and OVA 323-339
staining. The eosinophil-dominant inflammation was clearly visualized by MBP immunohistochemical staining. Furthermore, thickenings of the bronchial airway walls and increased mucus production were found in the OVA 323-339 mice, as well as the OVA mice (Figs 2 and 3).

IL-4 and IFN-γ profiles

An altered balance in the levels of inflammatory cytokines is an indicator of systemic, but not local inflammatory status; therefore, we measured both serum and BALF IL-4 and IFN-γ levels. In serum we found increased IL-4 levels in both the OVA and OVA 323-339-treated mice (37.3 ± 47.9 pg/ml and 71.9 ± 93.9 pg/ml, respectively) versus non-detectable levels in the control mice (Fig. 4A). Serum IFN-γ levels were under the detection limit in all samples of the three mice groups. In BALF samples, IFN-γ, IL-4 and total IgE all levels were equally under the detection limits.

Total IgE, OVA and OVA 323-339-specific IgE/IgG1/IgG2A levels in serum and BALF

Allergen-specific IgE antibodies will increase after sensitization, whereas different subclasses of IgG antibodies can be studied for an evaluation of immune tolerance. We detected higher serum total IgE levels (91.3 ± 9.2 ng/ml) in the OVA-treated mice than that in the control (8.7 ± 7.3 ng/ml). Also in support of this, we observed a significant increase in OVA-specific IgE in OVA-treated mice (0.39 ± 0.44 OD) when compared to saline-treated control animals in which no MBP-positive cells were detected in the airways. The figure is representative of five animals per group. Original magnification: 200×.
Table 1 Serum-specific IgG antibody levels in the studied research groups.

<table>
<thead>
<tr>
<th></th>
<th>OVA 323-339</th>
<th>Saline control</th>
</tr>
</thead>
<tbody>
<tr>
<td>OVA sp. IgG_{1}</td>
<td>0.90 ± 1.21</td>
<td>1.25 ± 1.41</td>
</tr>
<tr>
<td>OVA sp. IgG_{2A}</td>
<td>0.69 ± 0.67</td>
<td>0.50 ± 0.44</td>
</tr>
<tr>
<td>OVA 323-339 sp. IgG_{1}</td>
<td>1.04 ± 0.60</td>
<td>0.76 ± 0.62</td>
</tr>
<tr>
<td>OVA 323-339 sp. IgG_{2A}</td>
<td>0.35 ± 0.45</td>
<td>0.32 ± 0.34</td>
</tr>
</tbody>
</table>

The results are expressed in optical density values (OD) of the means ± standard deviations (SD). ANOVA was performed for the data analyses, and the comparisons were studied between allergens groups and saline-treated control group, P < 0.05 was considered as significant difference. No difference was found in OD between the groups. Sp., specific; Saline, saline-treated control group; n, the number of individuals.

The OVA and OVA 323-339-specific proliferation assay: OVA 323-339 epitope cannot activate OVA-sensitized and challenged mice splenocytes

To evaluate whether these allergen structures could activate T cells in cell culture, we isolated the splenocytes of each group and stimulated them with OVA or OVA 323-339. Splenocytes of both the OVA- and OVA 323-339-treated mice displayed a strong proliferative response after stimulation by OVA (5312 ± 1886 cpm and 7792 ± 5451 cpm, P < 0.05) when compared to the saline-treated control mice splenocyte response to OVA (2704 ± 2472 cpm). Medium as a control stimulant did not cause any significant difference in response between allergen-treated groups and saline-treated groups (OVA 1231 ± 86 cpm and OVA 323-339 group 2737 ± 1604 cpm vs. saline-treated control mice 1582 ± 1334 cpm, P > 0.05, respectively). Strong proliferative responses were induced by OVA 323-339 stimulation in splenocytes of OVA 323-339-treated mice (14343 ± 11232 cpm versus saline-treated control mice splenocyte response to OVA 323-339 1926 ± 1678 cpm, P < 0.01).

We also studied whether the readily processed epitope of OVA 323-339 could activate OVA or saline-treated mice splenocytes in culture. There was no significantly increased response to OVA 323-339 stimulus in the OVA-treated mice (2879 ± 1049 cpm, P > 0.05) versus saline-treated mice control (1926 ± 1678 cpm). In addition, there were no obvious differences observed in the cpm values between 100 μl or 200 μl of allergens which were used to stimulate the isolated splenocytes (Fig. 5.).

Discussion

The isolated splenocytes from OVA 323-339 or OVA-sensitized and challenged mice groups, when stimulated in cell culture with their respective allergens did demonstrate T-cell proliferation. However, unlike OVA, OVA 323-339 could not stimulate T-cell division of OVA-sensitized and challenged mice. Our in vivo results showed that after repeated intranasal challenge, both OVA 323-339 and OVA-treated mice groups developed a significantly increased inflammatory response in the target organ, which in this model is the airway. The specific IgE immunoglobulin levels were likewise increased by a significant difference when compared to the control.
A similar expression of morphology such as an increased eosinophil-dominant inflammation around the bronchi and vessels, and thickenings of bronchial walls and mucus over-secretion, was found in both OVA and OVA 323-339-sensitized and challenged mice in lung tissue histology and MBP immunohistochemistry. Augmented serum IL-4 production levels in mice treated with OVA and OVA 323-339 were also observed. Although no IFN-γ production could be detected in serum or BALF samples. Our results suggest that both OVA and OVA 323-339 were in vivo capable of producing cytokine-induced systemic and local inflammation. OVA-treated mice illustrated an increased total and OVA-specific IgE production, while OVA 323-339 mice only showed a significant increase in the production of OVA 323-339-specific IgE. A possible explanation for the decline of total IgE production using the peptide is that the entire OVA with multi immunogenic structures could display stronger immunogenicity than its peptides. However, higher OVA-specific IgE was also observed in OVA 323-339-treated mice and, in contrast, OVA 323-339-specific IgE level in OVA mice was much lower than that in OVA 323-339 mice, and no difference was found when compared to that of the control. An in vivo molar ratio between OVA 323-339 and OVA is more than 20:1. This may suggest that the production of peptide-specific cross-antibody to OVA could be a dose-dependent process which requires a certain threshold amount of the immunogen (in other words, a high dose of OVA may be needed) to get the target peptide sequence of intact OVA presented and expressed on the surface of APC cells to induce a detectable IgE production. Other structures from intact OVA may be considered to be dominant immunogenic structures, e.g. OVA 1-10. Of course, the impact of species variation or strain difference in the production of epitope-specific antibodies, of course, could not be ignored [19].

Immune responses to protein antigens are strongly influenced by the nature of the helper T lymphocytes (Th) subsets involved. Th1 cells can evoke cell-dependent immunity by IFN-γ production and inhibit the production of IL-4 by Th2 cells and Th2 cell proliferation in vitro [21]. Th1 cells also promote immunoglobulin class switching from specific IgG1 to specific IgG2a [22], which is dependent on the presence of activating Fcγ receptors [23, 24]. Therefore, it is not surprising that the in vivo serum levels of specific IgG2a did not show an increase when compared to the control mice as quite low IFN-γ levels were developed in our model. Th2 cells have been recognized to induce bronchial inflammation as a result of enhanced secretion of Th2 cytokines [25–29]. IL-4 is the exclusive IgE isotype switching factor, responsible for the over-production of IgE, and can promote immunoglobulin class switching to IgE and IgG1 [22]. In our experiment, an increased IgE without paralleled IgG1 production was possibly because of the short-term experiment protocol.

IgE has the capacity to bind high-affinity receptors (FcεRI) on mast cells and basophils, in addition to low-affinity receptors (FceRII) on lymphocytes and other inflammatory cells such as eosinophils, monocytes and platelets [3, 30]. The number of IgE binding epitopes varies in different allergens. Although the minimal requirements of an allergenic peptide were demonstrated to be four amino acids, a molecular size of 12–15 amino acids may be necessary for antibody binding which may be related to a requirement for helical conformation [7, 31]. OVA 323-339 is composed of 17 amino acids, which as expected, induced higher OVA 323-339-specific IgE [3].

Splenocyte stimulation with OVA induced an increased proliferative response as observed in both OVA and OVA 323-339-sensitized and challenged mice, while proliferation to OVA 323-339 only occurred in splenocytes of the OVA 323-339 mice and not in the OVA mice. Accordingly, cells stimulated with control culture medium demonstrated very low thymidine incorporation when compared with the responses to OVA and OVA 323-339 stimulation. The presented proliferative results are consistent with the results of Jansen et al. [32] who demonstrated that OVA 323-339 induced a proliferative response in cell cultures from OVA-challenged animals. From Figure 4, we can find no significant difference in proliferative responses between using 100 μl and 200 μl of allergens when cells were stimulated with identical allergens. This could imply that the in vitro proliferative response to OVA or OVA 323-339 is not dose dependent or our doses have already reached the upper limit for full splenocyte response.

The proliferative response assay demonstrated that OVA 323-339 in vitro stimulation did lead to splenocyte proliferation and activation in cultivated cells. This could suggest that small peptides such as OVA 323-339 can play their role by being presented and expressed on the membrane surface of activated splenocytes in the same way as OVA, which is consistent with previous ideas: OVA and OVA 323-339 share at least one common epitope structure [7, 8]. Importantly, the cellular proliferative responses to allergens were accompanied by increased humoral allergen-specific IgE antibody production, which strongly suggested that the splenocyte proliferative responses most probably were IgE-related.

To conclude, we suggest that OVA 323-339 can induce Th2-dominant immune responses, and that the splenocyte proliferative response to OVA 323-339 is possibly IgE-related much like that of OVA.

Acknowledgments

The authors thank Dr. James Lee (Mayo Clinic, Scottsdale, AZ, USA) for his kind gift of anti-mouse MBP.
antibody. We also thank Ann Kristin Heian Gulliksen, Judit Eriksen, Gred Lilian Hallseth and Randi Lavik Nygaard, whose skilful technical assistance is highly appreciated.

References

1 Langeland T, Harbitz O. A clinical and immunological study of allergy to hen’s egg white. V. Purification and identification of a major allergen (antigen 22) in hen’s egg white. Allergy 1983;38:131–9.
2 Holen E, Elsayed S. Specific T cell lines for ovalbumin, ovomucoid, lysozyme and two OA synthetic epitopes, generated from egg allergic patients’ PBMC. Clin Exp Allergy 1996;26:1080–8.